


EXHIBIT B

MEC Review

Percentage of Minorities on Medical Staff* vs. Percentage of Minorities Reviewed by MEC



* There were 991 physicians on medical staff, but ABSMC identified only 547 by race.


** One physician, identified by ABSMC as "Physician G," was reviewed twice by the MEC. He is treated here as two separate physicians in order to avoid undercounting MEC review of Caucasians.

*** ABSMC stated that the doctor it identified as "Physician H" is "Non African-American."

In fact, that doctor's race is a mix of predominantly Indian, African American and Native American. For that reason, he is treated here as African American.

EXHIBIT C

MEC Review by Race As Percentage of Medical Staff



* One physician, identified by ABSMC as "Physician G," was reviewed twice by the MEC. He is treated here as two separate physicians in order to avoid undercounting MEC review of Caucasians.

EXHIBIT D

Disciplined ABSMC Physicians, 2004-06

Race Comparison





EXHIBIT E

MEC Review by Race, for Standard of Care Issues As Percentage of Medical Staff



* One physician, identified by ABSMC as "Physician G," was reviewed twice by the MEC. He is treated here as two separate physicians in order to avoid undercounting MEC review of Caucasians.

EXHIBIT F

Summarily Suspended ABSMC Physicians, 2004-06

Race Comparison




EXHIBIT G

EAST BAY CARDIAC SURGERY CENTER
Medical Group

Specializing in Adult Cardiac Surgery and Thoracic Surgery

Leigh I.G. Iverson, M.D.
Coyness L. Ennix, Jr., M.D.
Russell D. Stanten, M.D.
Junaid H. Khan, M.D.

February 13, 2005

CONFIDENTIAL

William Isenberg, M.D., Ph.D.
President, Medical Staff
Alta Bates Summit Medical Center
350 Hawthorne Ave.
Oakland, CA. 94609

RE: Peer review of Dr. Coyness L. Ennix, Jr.

Dear Dr. Isenberg:


I was surprised and concerned to learn that an Ad Hoc Committee was sending 10 cases of Dr. Ennix's for an outside review.

I have been associated with Dr. Ennix in a practice of cardiac and thoracic surgery for about 5 years. We have been involved in several hundred cases together. I have known of his excellent reputation for at least 15 years. He is a nationally recognized for his leadership and innovation in cardiac surgery. He has without exception shown outstanding skill and judgment. I've have always respected his insight, technical abilities and judgment. It is my impression that he has been innovative and interested in new ideas and has added significantly to our practice.

I am not familiar with all 10 of the cases involved in this review but I am familiar with the four minimally invasive cases. I believe that after these four cases were peer reviewed by Dr. Hon lee, his review should have been accepted and these four cases closed. I'm not familiar enough with the other six cases to comment. However, in general cardiac surgery in 2005 still has significant risk and complications can occur. It is my understanding that Dr. Ennix's results over the last few years are statistically the same as for the national average when risk adjusted.

In summary, Dr. Ennix is a good surgeon with good judgment and technique. In addition, Dr. Ennix is a gentleman.

Sincerely yours,


Junaid Khan

cc: Steven Stanten, M.D.
Warren Kirk, CEO

3300 Webster Street, Suite 500 Oakland, California 94609-3149 (510) 465-6600 FAX: (510) 839-0806

D 4474

EXHIBIT H

SUMMIT MEDICAL CENTER
DEPARTMENT OF SURGERY PEER REVIEW
QUALITY INDICATORS

CONFIDENTIAL

100% SCREENING

- **Deaths- Intra-Op and Post-Op (w/in 30 Days of Surgery) and Non-Procedure Death w/ Surgeon as Attending**
(As of 11/06, it was decided that deaths following incidental tracheostomies would not be reviewed as "Post-Operative Deaths")
- **Returns to Surgery**
Excludes dialysis access cases

OTHER CASES BY REFERRAL

- **Risk Referrals**
- **Referral from Other Sources** (UOFs, Physicians, Other Committees, Critical Care Rounds, etc.)
- **JCAHO Monitor Referrals** (Blood Usage, Operative and Other Procedure Review, Medication Usage/ ADRs, Medical Records, Documentation, Core Measures)

***CARDIO-THORACIC SURGERY**

Deaths, Complications, Returns to Surgery: Cases involving cardiac surgery are reviewed by a separate Cardio-Thoracic Peer Review Committee. Physician peer review issues involving questionable sub-standard care/ requiring action are referred to the Surgery Peer Review Committee for follow-up. . Identified system issues are acted upon by that PI Committee (see below). CT indicators are also tracked/monitored via STS System (Society of Thoracic Surgery).

Cardiac Surgery has its own Multidisciplinary PI Meeting for identification of opportunities for Performance Improvement. This committee operates under the umbrella of, and its Performance Improvement activities are reported to, the Surgery Peer Review and/or Performance Improvement Committee.

RN CLOSURE CRITERIA

Deaths **** REFER TO MORTALITY REVIEW FLOW CHART**

Returns to Surgery (Note: Dialysis Access cases are not screened)

- **Complication :** a) recognized, and b) appropriate interventions taken, c) in a timely manner. No indication of care outside the standard is noted. These cases are "rated" in the MIDAS system.

Revised March, 1998, Surgery Quality

Reviewed/Approved June, 1999, January-02, 2004, February 2007




EXHIBIT I

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

COYNESS L. ENNIX, JR., M.D.,
as an individual and in his
representative capacity under
Business & Professions Code
Section 17200 et seq.,
Plaintiffs,

CERTIFIED COPY
CONFIDENTIAL

vs. No. C 07-2486
RUSSELL D. STANTEN, M.D.,
LEIGH I.G. IVERSON, M.D.,
STEVEN A. STANTEN, M.D.,
WILLIAM M. ISENBERG, M.D.,
Ph.D., ALTA BATES SUMMIT
MEDICAL CENTER and DOES 1
through 100,
Defendants.

-----/
DESIGNATED "CONFIDENTIAL"

DEPOSITION OF:

MARILYN BARKIN

Thursday, January 24, 2008

Reported by: HANNAH KAUFMAN & ASSOCIATES, INC.
Certified Shorthand Reporters

DARCY J. BROKAW 472 Pacheco Street
RPR, CRR, CLR, San Francisco, California 94116
CSR No. 12584

(415)664-4269

HANNAH KAUFMAN & ASSOCIATES, INC.

1 Q And how much time did you spend with
2 Mr. Vandall in consultation?

3 A About four hours, three or four hours.

4 Q And how much time did you spend going over
5 the documents you've just mentioned?

6 A Two or three hours.

7 Q When were you first notified that there
8 was a potential that you would have to testify as
9 what we call the Person Most Knowledgeable on peer
10 review at the departmental division level at Summit?

11 MR. VANDALL: I'll just object.

12 He doesn't want to know the contents of
13 any conversations that you and I had. He's just
14 asking you about timing.

15 BY MR. SWEET:

16 Q Well, I do want to know the contents of
17 the conversations, but I'm not entitled to them.

18 But what I am entitled to is to know when
19 you were first notified that you would potentially
20 be testifying as the Person Most Knowledgeable.

21 A To the best of my recollection, I think it
22 was about ten days ago, a week to ten days ago.

23 Q Okay. We'll flesh these concepts out a
24 little bit more as we go on here.

25 But my understanding is that at Summit,

HANNAH KAUFMAN & ASSOCIATES, INC.

1 there is a nurse level of review, there is a
2 physician level of review, there then is a
3 cardiothoracic division level of review, and then a
4 surgery division or department level of review; is
5 that accurate?

6 A Yes.

7 Q Will you generally tell me -- and again,
8 I'm going to ask you more specifics about this; so I
9 just really want general answers if you can give
10 them -- your role in the nurse, is it quality
11 improvement coordinator --

12 A Yes.

13 Q -- level of review.

14 A I review documents that are provided to me
15 by the organization that help me in identifying
16 cases that would meet the criteria for peer review,
17 meaning deaths, returns to surgery, CVAs and so
18 forth.

19 Q Ms. Barkin, are you the quality
20 improvement coordinator for the cardiothoracic
21 surgery group?

22 A Yes.

23 Q Okay. So there's not more than one?

24 A No.

25 Q Okay.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 MR. VANDALL: I'm going to object.

2 Ms. Barkin was not finished responding to your
3 question, and you should let her finish her answers
4 before you interrupt her.

5 BY MR. SWEET:

6 Q What about -- so you are the quality
7 improvement coordinator for the CT division?

8 A Yes.

9 Q What is your role in the -- what I look at
10 as the next level, the physician level of peer
11 review at Summit? And I'm just talking about
12 cardiothoracic cases.

13 A I understand.

14 When I identify cases that meet criteria,
15 I prepare a short abstract of the case and refer
16 it -- present that to the reviewing physician for
17 their determination.

18 Q Okay.

19 A And I also review the chart and flag the
20 appropriate documents.

21 Q Meet "criteria" is a word you just used.
22 Is that the same thing as indicators?

23 A Correct.

24 Q As the quality improvement coordinator for
25 the CT group or division, do you have it within your

HANNAH KAUFMAN & ASSOCIATES, INC.

1 gambit or power to close the case on your own at
2 that point?

3 MR. VANDALL: Objection; vague.

4 THE WITNESS: It is in my power. I rarely
5 do that.

6 BY MR. SWEET:

7 Q Okay. Sometimes, do you?

8 A I think I've closed one case over the last
9 year that I felt was -- didn't warrant
10 physician-level review.

11 Q If I understand -- tell me if this is
12 right or wrong -- the rules and regulations of
13 Summit allow for the quality improvement coordinator
14 to clear the case, don't they?

15 A Yes, they do.

16 Q And then you've indicated that once you
17 review a matter as the QIC, you then submit an
18 abstract; is that what you said?

19 A Correct.

20 Q What is the abstract called? Does it have
21 a name?

22 A It's just called the case abstract.

23 Q Is it a one-page document?

24 A It can be a lot less than that.

25 Q What type of information is on the case

HANNAH KAUFMAN & ASSOCIATES, INC.

1 until Dr. Iverson retired, whenever that was. It's
2 been over a year. So that would be seven, seven.
3 Except that Kaiser just added an additional surgeon,
4 so it's back up to eight.

5 Q So it sounds like as a general
6 proposition, there have been eight cardiac surgeons
7 in the cardiothoracic division since 2004?

8 A Between seven and eight. It varies at
9 times.

10 Q Can you name them all?

11 A Yes.

12 Q Please do so.

13 A Kaiser was, let's see, David Alyono,
14 A-l-y-o-n-o; Brian Cain, C-a-i-n; Hon, H-o-n, Lee,
15 L-e-e; Dennis Durzinsky, D-u-r-z-i-n-s-k-y.

16 The Summit group is Russell Stanten;
17 Coyness Ennix; Junaid, J-u-n-a-i-d, Kahn, K-a-h-n;
18 Leigh Iverson; it's L-e-i-g-h, Iverson,
19 I-v-e-r-s-o-n. And the new Kaiser physician who
20 started at the very end of last year is Daniel
21 Pellegrino.

22 I think that's all.

23 Q In that group you just listed, is
24 Dr. Ennix the only African-American surgeon?

25 A Yes.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 prior testimony.

2 BY MR. SWEET:

3 Q With maybe one exception, correct?

4 A I try to do all the abstracts on all the
5 cases that meet criteria.

6 Q Okay. And then it goes -- the matter goes
7 to a physician-level review, correct?

8 A Correct, yes.

9 Q Who chooses what physician will
10 participate in a physician-level review?

11 A The usual -- well, the procedure that's
12 followed is in the cardiothoracic division, if it's
13 one of the Summit cardiothoracic surgeons' cases, it
14 will go to a Kaiser physician for review and vice
15 versa. So if it's a Kaiser physician, it's going to
16 go to a Summit doc for review.

17 Q Why? Why that procedure?

18 A To avoid -- to try to keep the process as
19 objective as possible.

20 Q Whose idea was that, to send Summit
21 matters to Kaiser physicians and vice versa?

22 A I can't answer that. I don't know.

23 Q Was that process in place before you
24 assumed the position?

25 A Yes.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 Q Does it remain in place today?

2 A Yes.

3 Q Has Dr. Russell Stanten ever suggested
4 that that be changed in any way?

5 A No.

6 Q Has anybody --

7 A Or not to me, he has not suggested it.

8 Q Has anybody ever suggested that that be
9 changed in any way?

10 MR. VANDALL: Objection; vague.

11 THE WITNESS: I'm not aware.

12 BY MR. SWEET:

13 Q Who chooses the specific physician that
14 will act as a reviewer?

15 A For the most part, and -- well, I'm going
16 to say it depends. For the most part, I distribute
17 the cases to the Kaiser physicians based on their
18 availability and who's done the last -- the most the
19 last time. Somebody else is going to get the next
20 batch of cases.

21 Occasionally, Dr. Stanten will --
22 Dr. Stanten is aware of all the cases that I'm going
23 to have reviewed either by him or our cases that go
24 to Kaiser. As chief of the department, he's made
25 aware of all the cases that need review, whether

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A You know, I believe Dr. Iverson was
2 reviewing them.

3 Q All of the Kaiser cases?

4 A I'd be speculating.

5 Q Okay. Are you saying that you do not make
6 the decision when a Kaiser case needs
7 physician-level review on which Summit physician
8 will review it?

9 A That would be correct.

10 Q Why is that, do you know?

11 MR. VANDALL: Calls for speculation.

12 THE WITNESS: I don't know. You'd have
13 to ...

14 BY MR. SWEET:

15 Q This process, the physician-level review,
16 the Kaiser docs reviewing Summit and vice versa, is
17 that consistent with other peer reviews that you've
18 become aware of in your career, other divisional or
19 departmental peer reviews?

20 MR. VANDALL: Objection; compound, vague,
21 incomplete hypothetical, lacks foundation.

22 THE WITNESS: In the sense that physicians
23 who are part of the formal group do not generally
24 review each other's -- do not review a case of
25 another member from their group.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 BY MR. SWEET:

2 Q So that -- I don't want to put words in
3 your mouth, but it sounds standard for the
4 physician-level-review peer review to be handled in
5 the manner that the CT division handles it.

6 A That would be --

7 MR. VANDALL: Objection; vague,
8 argumentative and misstates the prior testimony.

9 BY MR. SWEET:

10 Q Is that right?

11 A In order to keep the process objective,
12 you try to find -- well, you find reviewers who are
13 on the committee -- the cases are reviewed by
14 someone who's on the peer review committee. They're
15 not just parsed out to anybody on the medical staff.
16 And physicians who are in the same group do not
17 review each other's cases.

18 Q Okay. So the answer to my question on
19 whether this process at the Summit CT division,
20 where one group reviews the other group's cases, is
21 a common practice, right?

22 MR. VANDALL: Objection; vague
23 argumentative, misstates the testimony.

24 THE WITNESS: Well, I don't know if it's
25 common elsewhere, but, you know -- I don't know

HANNAH KAUFMAN & ASSOCIATES, INC.

1 whether it's common or not. That's the way -- what
2 I've told you is the way that it's done in the CT
3 division and by other departments at Summit.

4 BY MR. SWEET:

5 Q Like what other departments, if you know?

6 A Cardiology, for example. There are
7 several different cardiology practice groups.

8 Q And you were mentioning the reason it's
9 done this way -- and I don't want to put words in
10 your mouth; tell me if this is accurate -- is that's
11 the fair way to do it; is that right?

12 MR. VANDALL: Objection; misstates prior
13 testimony, argumentative, vague.

14 THE WITNESS: It would be to make sure
15 that the reviewer could be objective in their review
16 and wouldn't be biased.

17 BY MR. SWEET:

18 Q In the CT division, in your experience
19 there since 2004, has that process worked with the
20 physician-level review as you've just described it?

21 MR. VANDALL: Objection; calls for
22 speculation, calls for a legal conclusion, vague.

23 BY MR. SWEET:

24 Q Has it been fair and objective, like it's
25 supposed to be?

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A I can't -- I have no way of answering
2 that.

3 Q Well, do you sit in the cardiothoracic
4 peer review committee meetings?

5 A Yes, I do.

6 Q So you have an opportunity to see that
7 process play out, don't you, the peer review process
8 play out?

9 A With respect to cases that go to the
10 committee level.

11 Q Okay. Well, back to the physician level,
12 have you -- do you have a concern about the
13 objectivity of the physician-level review in the CT
14 division?

15 MR. VANDALL: Objection; vague, calls for
16 a personal conclusion. It's outside the scope of
17 this 30(b)(6) deposition.

18 THE WITNESS: Are you asking me for a
19 personal opinion or -- or whether I think the
20 process is fair?

21 BY MR. SWEET:

22 Q As an institution, does Summit believe
23 that that physician-level review, as you've
24 described it, in the CT division is fair?

25 A I believe they do.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 Q Has anybody ever voiced an opinion to you
2 to the contrary, that it's not fair?

3 MR. VANDALL: Objection; vague, calls for
4 speculation, incomplete hypothetical.

5 THE WITNESS: No one has voiced an opinion
6 to me.

7 MR. VANDALL: Do you want to take a
8 two-minute break?

9 MR. SWEET: That's fine. We've been going
10 an hour. Let's do that. Thank you for the
11 suggestion.

12 (A brief recess was taken.)

13 BY MR. SWEET:

14 Q Ms. Barkin, I want to change gears for
15 just a minute and ask you this question. Each of
16 the physicians at Summit has a physician number; is
17 that right?

18 A Yes.

19 Q How are those numbers assigned to the
20 physician?

21 A I think they come directly out of the
22 system.

23 Q Are they chronologically assigned? In
24 other words, the doctors who have been there longer
25 have lower numbers than the doctors who have been

HANNAH KAUFMAN & ASSOCIATES, INC.

1 BY MR. SWEET:

2 Q Do you remember the last question?

3 A No.

4 Q Okay.

5 (The record was read back by the reporter as follows:

6 "Q When a case proceeds from
7 the physician-level review to
8 the cardiothoracic peer review
9 committee level -- I'm sure I'm
10 messing these words up.

11 "A Come again. What did you
12 just say?

13 "Q I'm working up the ladder
14 here. We're going from
15 physician level --

16 "MR. VANDALL: Objection.

17 "Q -- to cardiothoracic
18 surgery peer review committee
19 level.")

20 BY MR. SWEET:

21 Q I want to know the process, after the
22 physician level, of the cases that go to the CT peer
23 review committee.

24 A So to clarify what you're asking,
25 physician -- a physician-level case gets elevated to

HANNAH KAUFMAN & ASSOCIATES, INC.

1 go to the committee, and you're asking --

2 Q What happens with the case at that point?

3 A The case comes to the committee, the
4 cardiothoracic peer review committee, and it's
5 discussed. And a determination as to the
6 appropriateness of the care or any concerns is read
7 into the minutes, and the case is either closed or
8 it could be left open for a deferred determination,
9 depending on additional information.

10 Q How often does the CT surgery peer review
11 committee meet?

12 MR. VANDALL: Objection; vague as to time.

13 THE WITNESS: The model is quarterly.
14 Occasionally, those meetings get cancelled or
15 deferred because of scheduling conflicts.

16 BY MR. SWEET:

17 Q And are those meetings specifically
18 cardiothoracic surgery peer review committee
19 meetings?

20 A Yes.

21 Q And the only thing discussed at those are
22 peer review matters?

23 A What time frame are you asking about?

24 Q Well, has it changed over time?

25 A Yes.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 review matters involving CT division members that
2 start at the CT committee level?

3 MR. VANDALL: Objection; vague, compound.

4 THE WITNESS: Well, to clarify, the
5 percentage of cases that start at the committee
6 level?

7 BY MR. SWEET:

8 Q Yes.

9 A They generally don't start at the
10 committee level. I mean -- well, at the
11 department -- and I'm only speaking to the CT
12 surgery department level; I'm not speaking to
13 anything higher up. But at my level, a case would
14 generally start at the QIC or the physician reviewer
15 level and then rise.

16 Q Have you ever heard of a peer review
17 matter starting at the CT division peer review
18 committee level?

19 MR. VANDALL: Objection; vague.

20 THE WITNESS: Meaning that it would not
21 have been entered into the database before the
22 committee meeting?

23 BY MR. SWEET:

24 Q Because there was no QIC or
25 physician-level review, yes.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A I can't recall that happening. That would
2 be outside of standard operating procedures.

3 Q And let's talk a little bit more about the
4 CT peer review committee meeting itself.

5 What do the physicians have available to
6 them to consider when discussing the peer review
7 matters? In other words, do they have the charts
8 there? What do they consider?

9 A They have the charts.

10 MR. VANDALL: Objection; vague.

11 THE WITNESS: I'm sorry.

12 MR. VANDALL: It's okay.

13 BY MR. SWEET:

14 Q They have the charts there?

15 A They have the chart.

16 Q Of all of the matters that come to the CT
17 division peer review committee level, all the peer
18 review matters that come there, what percentage of
19 those proceed to the surgery peer review committee?

20 A During the time that I've been
21 functioning, I don't believe that any cases have
22 gone directly from the CT department, CT peer review
23 committee to the surgery committee.


24 Q Is it true that -- I'm covering different
25 paths here. But is it true also that no case has

STATE OF CALIFORNIA

I do hereby certify that the witness in the foregoing deposition was by me duly sworn to testify the truth, the whole truth, and nothing but the truth in the within-entitled cause; that said deposition was taken at the time and place therein stated; that the testimony of the said witness was reported by me, a Certified Shorthand Reporter and a disinterested person, and was under my supervision thereafter transcribed into typewriting; that thereafter, the witness was given an opportunity to read and correct the deposition transcript, and to subscribe the same; that if unsigned by the witness, the signature has been waived in accordance with stipulation between counsel for the respective parties.

And I further certify that I am not of counsel or attorney for either or any of the parties to said deposition, nor in any way interested in the outcome of the cause named in said caption.

IN WITNESS WHEREOF, I have hereunto set my hand the 5th
day of February, 2008.


Certified Shorthand Reporter
CSR No. 12584